文献速递眼底病与葡萄膜炎

补体C3抑制剂Pegcetacoplan治疗年龄相关性黄斑变性继发地图样萎缩:一项随机2期试验

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
PubMed 文献 · Ophthalmology · 2019-07-16

这项前瞻性、多中心、随机、假注射对照的2期研究纳入246例地图样萎缩患者,按2:2:1:1随机接受15 mg pegcetacoplan(C3抑制剂)玻璃体腔注射每月或隔月,或假注射每月或隔月,共12个月。每月组GA病变面积增长较假注射组降低29%(95%CI 9-49;P=0.008),隔月组降低20%(95%CI 0-40;P=0.067)。作者结论认为局部C3抑制可统计学显著减少GA增长,3期研究将进一步明确疗效与安全性。

要点

  • 每月pegcetacoplan组GA增长较假注射组降低29%(95%CI 9-49;P=0.008),隔月组降低20%(95%CI 0-40;P=0.067)。
  • 事后分析显示治疗第2个6个月效应更大,每月组降低45%(P=0.0004),隔月组降低33%(P=0.009)。
  • 每月组发生2例培养阳性眼内炎和1例培养阴性眼内炎;新生渗出性AMD在pegcetacoplan治疗眼更常见(每月组18/86眼[20.9%],隔月组7/79眼[8.9%])vs 假注射组1/81眼[1.2%]。

核心结论

  • 局部C3抑制 with pegcetacoplan 与假注射相比可统计学显著减少GA增长。
  • 3期研究将进一步明确疗效与安全性。

研究设计与样本

  • 前瞻性、多中心、随机、假注射对照的2期研究。
  • 纳入246例GA患者,按2:2:1:1随机接受15 mg pegcetacoplan玻璃体腔注射每月或隔月,或假注射每月或隔月,共12个月,第15和18个月随访。
  • 采用眼底自发荧光成像测量GA面积与增长。
  • 主要疗效终点为基线至第12个月GA病变面积平方根的平均变化。
  • 主要安全性终点为治疗中出现的不良事件数量与严重程度。

主要发现

  • 每月pegcetacoplan组GA增长率较假注射组降低29%(95%CI 9-49;P=0.008),隔月组降低20%(95%CI 0-40;P=0.067)。
  • 事后分析显示治疗第2个6个月效应更大,每月组降低45%(P=0.0004),隔月组降低33%(P=0.009)。
  • 每月pegcetacoplan组发生2例培养阳性眼内炎和1例培养阴性眼内炎。
  • 新生、研究者判定的渗出性AMD在pegcetacoplan治疗眼更常见:每月组18/86眼(20.9%),隔月组7/79眼(8.9%),假注射组1/81眼(1.2%)。

关键数值与推荐

  • 主要疗效终点为基线至第12个月GA病变面积平方根的平均变化。
  • 次要结局包括未平方根转换的GA病变面积自基线平均变化、GA病变距中心凹距离、最佳矫正视力、低亮度最佳矫正视力和低亮度视力缺损。
  • 主要安全性终点为治疗中出现的不良事件数量与严重程度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出3期研究将进一步明确疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause of blindness. Even while central visual acuity remains relatively well preserved, GA often causes considerable compromise of visual function and quality of life. No treatment currently exists. We evaluated the safety and efficacy of pegcetacoplan, a complement C3 inhibitor, for treatment of GA. DESIGN: Prospective, multicenter, randomized, sham-controlled phase 2 study. PARTICIPANTS: Two hundred forty-six patients with GA. METHODS: Patients with GA were assigned randomly in a 2:2:1:1 ratio to receive intravitreal injections of 15 mg pegcetacoplan monthly or every other month (EOM) or sham intravitreal injections monthly or EOM for 12 months with follow-up at months 15 and 18. Area and growth of GA were measured using fundus autofluorescence imaging. MAIN OUTCOME MEASURES: The primary efficacy end point was mean change in square root GA lesion area from baseline to month 12. Secondary outcome measures included mean change from baseline in GA lesion area without the square root transformation, distance of GA lesion from the fovea, best-corrected visual acuity (BCVA), low-luminance BCVA, and low-luminance visual acuity deficit. The primary safety end point was the number and severity of treatment-emergent adverse events. RESULTS: In patients receiving pegcetacoplan monthly or EOM, the GA growth rate was reduced by 29% (95% confidence interval [CI], 9-49; P = 0.008) and 20% (95% CI, 0-40; P = 0.067) compared with the sham treatment group. Post hoc analysis showed that the effect was greater in the second 6 months of treatment, with observed reductions of 45% (P = 0.0004) and 33% (P = 0.009) for pegcetacoplan monthly and EOM, respectively. Two cases of culture-positive endophthalmitis and 1 case of culture-negative endophthalmitis occurred in the pegcetacoplan monthly group. New-onset investigator-determined exudative AMD was reported more frequently in pegcetacoplan-treated eyes (18/86 eyes [20.9%] and 7/79 eyes [8.9%] in monthly and EOM groups, respectively) than in sham-treated eyes (1/81 eyes [1.2%]). CONCLUSIONS: Local C3 inhibition with pegcetacoplan resulted in statistically significant reductions in the growth of GA compared with sham treatment. Phase 3 studies will define the efficacy and safety profile further.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2019. PMID: 31474439. doi:10.1016/j.ophtha.2019.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。